Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lymphocyte therapy of renal cell carcinoma.

Expert review of anticancer therapy - 1 Dec 2005

Dillman Robert O

Abstract excerpt

During the past 20 years, there has been considerable interest in lymphocyte therapy as a treatment for renal cell carcinoma. There is no therapeutic role for B-lymphocyte therapy, but their products, monoclonal antibodies, now have widespread clinical applications. The major types of autologous lymphocyte therapy that have been explored in clinical trials are cytotoxic lymphokine-activated killer cells, which...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Phenotype
Share to T-Lymphocytes
Share to Antigens, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Renal Cell

Share to Immunologic Memory

Share to Immunotherapy

Share to Kidney Neoplasms

Share to Killer Cells, Natural

Source

Identifiers

PMID: 16336095
DOI: 10.1586/14737140.5.6.1041

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lymphocyte therapy of renal cell carcinoma.PMID 16336095Read ↗

Evolution of cell therapy for renal cell carcinomaSemantic proximity Read ↗

Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma.Semantic proximity Read ↗

Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas.Semantic proximity Read ↗

Improved lymphocyte cytotoxicity against murine renal cell carcinoma.Semantic proximity Read ↗

Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.Semantic proximity Read ↗

T-lymphocyte subsets in the peripheral blood of patients with renal cell carcinoma.Semantic proximity Read ↗

Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: II. Characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation.Semantic proximity Read ↗

Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma.Semantic proximity Read ↗

Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. Phenotypic and functional analysis of the peripheral blood mononuclear cells.Semantic proximity Read ↗

Cytolytic effector cells against human tumors: distinguishing phenotype and function.Semantic proximity Read ↗

Regulatory effects of interleukin-4 on tumor-infiltrating lymphocytes derived from human renal cell carcinoma.Semantic proximity Read ↗

Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.